Evidence map›Paper›PMID 28793332›Full record

ArticlePloS one2017

Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis.

Ivy Y Choi, Olga N Karpus, Jason D Turner, Debbie Hardie, Jennifer L Marshall, Maria J H de Hair, Karen I Maijer, Paul P Tak, Karim Raza, Jörg Hamann and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Fibroblast pathology in inflammatory diseases.The Journal of clinical investigation · 2021
    Review
  13. Review
  14. Review
  15. Emerging Roles of Perivascular Mesenchymal Stem Cells in Synovial Joint Inflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ivy Y ChoiDivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3542-4909
Olga N KarpusDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Jason D TurnerRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Debbie HardieRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Jennifer L MarshallRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Maria J H de HairDivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Karen I MaijerDivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Paul P TakDivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Karim RazaRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Jörg HamannDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Christopher D BuckleyRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Danielle M GerlagDivision of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Andrew FilerRheumatology Research Group, Institute of Inflammation and Ageing, The University of Birmingham, United Kingdom.
Amsterdam UMC Location University of Amsterdam · NLUniversity of Birmingham · GBSandwell & West Birmingham Hospitals NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionPrevious studies have shown increased expression of stromal markers in synovial tissue (ST) of patients with established rheumatoid arthritis (RA). Here, ST expression of stromal markers in early arthritis in relationship to diagnosis and prognostic outcome was studied.

methodsST from 56 patients included in two different early arthritis cohorts and 7 non-inflammatory controls was analysed using immunofluorescence to detect stromal markers CD55, CD248, fibroblast activation protein (FAP) and podoplanin. Diagnostic classification (gout, psoriatic arthritis, unclassified arthritis (UA), parvovirus associated arthritis, reactive arthritis and RA), disease outcome (resolving vs persistent) and clinical variables were determined at baseline and after follow-up, and related to the expression of stromal markers.

resultsWe observed expression of all stromal markers in ST of early arthritis patients, independent of diagnosis or prognostic outcome. Synovial expression of FAP was significantly higher in patients developing early RA compared to other diagnostic groups and non-inflammatory controls. In RA FAP protein was expressed in both lining and sublining layers. Podoplanin expression was higher in all early inflammatory arthritis patients than controls, but did not differentiate diagnostic outcomes. Stromal marker expression was not associated with prognostic outcomes of disease persistence or resolution. There was no association with clinical or sonographic variables.

conclusionsStromal cell markers CD55, CD248, FAP and podoplanin are expressed in ST in the earliest stage of arthritis. Baseline expression of FAP is higher in early synovitis patients who fulfil classification criteria for RA over time. These results suggest that significant fibroblast activation occurs in RA in the early window of disease.

Indexed as

AdultAgedAntigens, CDAntigens, NeoplasmArthritisBiomarkersCD55 AntigensDisease ProgressionEndopeptidasesFemaleFibroblast Activation Protein AlphaFibroblastsGelatinasesHumansMaleMembrane GlycoproteinsAntigens, CDAntigens, NeoplasmBiomarkersCD248 protein, humanCD55 AntigensEndopeptidasesFibroblast Activation Protein AlphaGelatinasesMembrane GlycoproteinsMembrane ProteinsPDPN protein, humanPodoplaninSerine Endopeptidases

Identifiers

PMID28793332
PMCPMC5549962
OpenAlexW2742585051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.